John P. Northcott
Net Worth
Last updated:
What is John P. Northcott net worth?
The estimated net worth of Mr. John P. Northcott is at least $11,304,680 as of 16 May 2022. He owns shares worth $5,973,100 as insider, has earned $691,580 from insider trading and has received compensation worth at least $4,640,000 in Nektar Therapeutics.
What is the salary of John P. Northcott?
Mr. John P. Northcott salary is $1,160,000 per year as Senior Vice President & Chief Commercial Officer in Nektar Therapeutics.
How old is John P. Northcott?
Mr. John P. Northcott is 47 years old, born in 1978.
What stocks does John P. Northcott currently own?
As insider, Mr. John P. Northcott owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | Senior Vice President & Chief Commercial Officer | 223,210 | $26.76 | $5,973,100 |
What does Nektar Therapeutics do?
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
John P. Northcott insider trading
Nektar Therapeutics
Mr. John P. Northcott has made 6 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently he sold 4,592 units of NKTR stock worth $18,138 on 16 May 2022.
The largest trade he's ever made was exercising 15,358 units of NKTR stock on 16 Feb 2021. As of 16 May 2022 he still owns at least 223,210 units of NKTR stock.
Nektar Therapeutics key executives
Nektar Therapeutics executives and other stock owners filed with the SEC:
- Dr. Jonathan Zalevsky (50) Chief R&D Officer
- Mr. Gilbert M. Labrucherie J.D. (53) Senior Vice President, Chief Financial Officer & Chief Operating Officer
- Mr. Howard W. Robin (72) Chief Executive Officer, Pres & Director
- Mr. John P. Northcott (47) Senior Vice President & Chief Commercial Officer
- Mr. Mark A. Wilson (53) Senior Vice President, Gen. Counsel & Sec.